Sudeep Pharma Q2FY27 Results and Expansion Updates
Sudeep Pharma Ltd 路 Investor Presentation 路 29 Oct 2026, 1:36 am
Sudeep Pharma Q2FY27 Results and Expansion Updates Sudeep Pharma reported a record Q2FY27 performance, with consolidated revenue rising 21% YoY to Rs 196.7 crore and EBITDA growing 32% YoY to Rs 73.2 crore (margin at 37.2%, up ~70 bps). PAT rose 11% YoY to Rs 51.8 crore. For H1FY27, revenue reached Rs 355.0 crore (+23% YoY) with PAT at Rs 92.4 crore (+18% YoY). Key growth catalysts include USFDA approval for the 51,200 MT Nandesari facility and the upcoming Phase-1 25,000 MTPA battery-grade iron phosphate Dahej project targeted for completion by Mar'27.
Original exchange filing (PDF)
More announcements from Sudeep Pharma Ltd
- Submission of Transcript for the Earnings call held on 29.10.2026 路 03 Nov 2026
- Submission of Audio Recording of the Earnings call held on 29th October 2026 路 29 Oct 2026
- Outcome of Board Meeting 路 28 Oct 2026
- Submission of Unaudited Financials Results for the Quarter and half year ended 30th September 2026 路 28 Oct 2026
- Submission of Outcome of Board Meeting 路 28 Oct 2026
- Press Release - FDA Approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat. 路 26 Oct 2026
- Intimation for the Investor Meet Scheduled to be held on 29th October 2026 at 12:00 noon. 路 29 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 28 Oct 2026
